PDL BioPharma, Inc.
PDLINext catalyst
No upcoming catalyst in our data
No upcoming FDA decision, filing or trial readout is on file for PDLI. That does not mean none is planned.
Get an email about PDLI's next catalysts
Track PDL BioPharma (PDLI) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
0 upcoming, 0 past
No catalysts found.
Market Overview
Stock performance and key metrics
Daclizumab (Anti-CD25 Humanized Monoclonal Antibody)
Multiple Sclerosis
M200 (volociximab) in Combination with Dacarbazine (DTIC)
Melanoma
Visilizumab
Severe Ulcerative Colitis
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Daclizumab (Anti-CD25 Humanized Monoclonal Antibody) | Phase 2 | Multiple Sclerosis | - | - |
M200 (volociximab) in Combination with Dacarbazine (DTIC) | Phase 2 | Melanoma | - | - |
Visilizumab | Phase 2 | Severe Ulcerative Colitis | - | - |
Frequently asked questions
What is in PDL BioPharma, Inc.'s drug pipeline?β
CatalystAlert tracks 3 drug candidates in PDL BioPharma, Inc.'s (PDLI) pipeline across Phase 2. Its lead program is Daclizumab (Anti-CD25 Humanized Monoclonal Antibody) (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is PDL BioPharma, Inc.'s next FDA catalyst?β
CatalystAlert tracks every upcoming catalyst for PDL BioPharma, Inc. (PDLI) β PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings β each confidence-rated as confirmed, estimated or AI-detected.
How do I track PDLI biotech catalysts?β
Add PDLI to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow PDL BioPharma, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page β sourced from ClinicalTrials.gov, FDA and SEC filings.
